Heterologous COVID-19 Vaccination Strategies and Immune Responses

Heterologous COVID-19 vaccination—often termed mix-and-match immunisation—combines different vaccine platforms for priming and booster doses to optimise breadth, magnitude and durability of immune protection. By pairing viral-vector, mRNA, inactivated or recombinant protein vaccines in various sequences, researchers have sought to amplify neutralising antibody titres, diversify T cell repertoires and strengthen memory B cell pools. Such strategies address waning immunity, supply constraints and variant emergence by exploiting complementary modes of antigen presentation. Adenoviral and inactivated viral primes often enhance cellular responses, while mRNA or protein boosters drive potent humoral recall, particularly against spike-protein receptor-binding domains. Durability of protection, reactogenicity profiles and correlates of protection vary with vaccine order and interval, guiding policy for global booster campaigns. In practice, heterologous regimens have demonstrated improved cross-neutralisation of Delta, Omicron and other variants, offering flexible pathways to sustain high levels of population immunity.

Research from Nature Portfolio

High-dimensional immune profiling of sixteen vaccine combinations spanning adenoviral, mRNA and inactivated platforms revealed that heterologous regimens consistently outperformed homologous schedules in eliciting both spike-specific antibody and T cell responses. An mRNA booster following a viral-vector or inactivated priming dose yielded the strongest antibody titres and expanded spike-binding memory B cells, while inactivated primes enhanced T cell activation. Detailed lymphocyte signature analysis identified phenotypic markers correlating with superior neutralisation breadth.

A comparative study of a recombinant spike protein booster against a homologous mRNA booster demonstrated that heterologous protein boosting induced more sustained receptor-binding domain (RBD)-specific IgG titres with broader recognition of antigenic variants, alongside distinct natural killer cell dynamics linked to enhanced antibody durability. Profiles of adverse events did not compromise the favourable immunogenicity of the heterologous schedule.

Analysis of individuals primed with two doses of inactivated vaccine and boosted with mRNA showed restoration of potent neutralisation against ancestral, Delta and Omicron strains. Whereas two inactivated doses alone yielded minimal activity against Omicron, the mRNA booster elevated neutralising antibodies to levels comparable or superior to those achieved by two-dose mRNA regimens, underscoring the role of heterologous boosting in variant defence.

Heterologous COVID-19 Vaccination Strategies and Immune Responses publication trend

The graph below shows the total number of articles in heterologous covid-19 vaccination strategies and immune responses across all publications each year (not limited to Nature Index journals).

Technical terms

Heterologous vaccination: Administration of priming and booster doses using different vaccine platforms.

Neutralising antibody: Antibody that inhibits viral entry into host cells by blocking key surface proteins.

Geometric mean titre (GMT): Statistical measure of central tendency for antibody levels, emphasising proportional changes.

Receptor-binding domain (RBD): Portion of the viral spike protein that binds the host ACE2 receptor, critical for viral entry.

Th1 response: T helper type 1-dominated cellular response characterised by interferon-γ production and antiviral activity.

Memory B cell: Long-lived B lymphocyte that retains antigenic memory for rapid antibody production upon re-exposure.

References

1. Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines. Signal Transduction and Targeted Therapy (2024).
2. High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity. Nature Immunology (2023).
3. Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. Nature Communications (2023).
4. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial. The Lancet Microbe (2023).
5. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. The Lancet (2022).
6. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine (2022).